Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzuloparib and Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT05819060Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Apr 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib in ovarian cancer, sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 1.5 years. Status: unknown.
02
Drugs
fluzoparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05819060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05819060.